EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression

被引:4
|
作者
Ling, Wen [1 ]
Johnson, Sarah K. [1 ]
Mehdi, Syed J. [1 ]
Alapat, Daisy, V [1 ]
Bauer, Michael [1 ]
Zangari, Maurizio [1 ]
Schinke, Carolina [1 ]
Thanendrarajan, Sharmilan [1 ]
van Rhee, Frits [1 ]
Yaccoby, Shmuel [1 ]
机构
[1] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Myeloma Ctr, Dept Internal Med, Little Rock, AR 72205 USA
关键词
myeloma; pericytes; angiogenesis; mesenchymal cells; microenvironment; RISK MULTIPLE-MYELOMA; TUMOR-GROWTH; GAMMOPATHY; THERAPY; GENES; MGUS;
D O I
10.3390/cancers15184519
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In multiple myeloma, malignant plasma cells accumulate in the bone marrow. The symptoms and complications include osteolytic bone disease, anemia, reduced kidney function, immunosuppression, and induction of tumor-associated angiogenesis. Mesenchymal cells are important components of bone marrow niches; studying their dysfunctional activities reveals key features in myeloma pathogenies and improves therapies. We discovered that a subset of mesenchymal cells that express the receptor EDNRA are more prevalent in bone marrow areas infiltrated with tumor cells. In normal conditions, these cells are attached to blood vessels and mediate their functions; but in myeloma they seem to detach and accumulate in the interstitial marrow. The proportion of EDNRA-expressing cells and the expression of EDNRA in bone biopsies is low in premalignant stages and highest in high-risk myeloma patients. EDNRA could serve as a useful novel clinical biomarker of disease progression and dysfunctional bone marrow vasculature.Abstract Multiple myeloma (MM) induces dysfunctional bone marrow (BM) mesenchymal cells and neoangiogenesis. Pericytes and smooth muscle cells (SMCs) could detach from vessels and become cancer-associated fibroblasts. We found that the pericyte and SMC marker endothelin receptor type A (EDNRA) is overexpressed in whole MM bone biopsies; we sought to characterize its expression. EDNRA expression gradually increased with disease progression. High-risk MM patients had higher EDNRA expression than low-risk MM patients and EDNRA expression was highest in focal lesions. High EDNRA expression was associated with high expression of pericyte markers (e.g., RGS5, POSTN, and CD146) and the angiogenic marker FLT1. A single-cell analysis of unexpanded BM mesenchymal cells detected EDNRA expression in a subset of cells that coexpressed mesenchymal cell markers and had higher expression of proliferation genes. Immunohistochemistry revealed that the number of EDNRA+ cells in the interstitial BM increased as MM progressed; EDNRA+ cells were prevalent in areas near the MM focal growth. EDNRA+ cells were detached from CD34+ angiogenic cells and coexpressed RGS5 and periostin. Therefore, they likely originated from pericytes or SMCs. These findings identify a novel microenvironmental biomarker in MM and suggest that the presence of detached EDNRA+ cells indicates disrupted vasculature and increased angiogenesis.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13
    Zhang, Guihua
    Miao, Faan
    Xu, Jinge
    Wang, Rui
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2020, 20 (02) : 209 - 217
  • [42] Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional Morphology on Disease Progression
    Fernandez de Larrea, Carlos
    Tovar, Natalia
    Rozman, Maria
    Rosinol, Laura
    Ignacio Arostegui, Juan
    Teresa Cibeira, Maria
    Rovira, Montserrat
    Yaguee, Jordi
    Blade, Joan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (07) : 1084 - 1087
  • [43] Use of Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Could Increase the Risk of Cancer Progression Reply
    Brennen, W. Nathaniel
    Schweizer, Michael T.
    Wang, Hao
    Bivalacqua, Trinity J.
    Partin, Alan W.
    Lim, Su Jin
    Chapman, Carolyn
    Abdallah, Rehab
    Levy, Oren
    Bhowmick, Neil A.
    Karp, Jeffrey M.
    De Marzo, Angelo
    Isaacs, John T.
    Denmeade, Samuel R.
    STEM CELLS TRANSLATIONAL MEDICINE, 2019, 8 (07) : 739 - 740
  • [44] Microvesicles from bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by transferring thrombospondin-2
    Qi, Cuihua
    Shi, Huiying
    Fan, Mengke
    Chen, Weigang
    Yao, Hailing
    Jiang, Chen
    Meng, Lingjun
    Pang, Suya
    Lin, Rong
    CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
  • [45] Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
    Gebraad, Arjen
    Ohlsbom, Roope
    Miettinen, Juho J.
    Emeh, Promise
    Pakarinen, Toni-Karri
    Manninen, Mikko
    Eskelinen, Antti
    Kuismanen, Kirsi
    Slipicevic, Ana
    Lehmann, Fredrik
    Nupponen, Nina N.
    Heckman, Caroline A.
    Miettinen, Susanna
    CELLS, 2022, 11 (09)
  • [46] Influence of Wound Fluid on the Transdifferentiation of Human Mesenchymal Bone Marrow Stem Cells into Cancer-Associated Fibroblasts
    Moratin, Helena
    Boehm, Sonja
    Hagen, Rudolf
    Scherzad, Agmal
    Hackenberg, Stephan
    CELLS TISSUES ORGANS, 2023, 212 (04) : 304 - 316
  • [47] Bone Marrow-derived Mesenchymal Stem Cells and Chronic Allograft Disease in a Bronchiolitis Obliterans Animal Model
    Gomez de Antonio, David
    Campo-Canaveral de la Cruz, Jose Luis
    Zurita, Mercedes
    Santos, Martin
    Gonzalez Lois, Carmen
    Varela de Ugarte, Andres
    Vaquero, Jesus
    ARCHIVOS DE BRONCONEUMOLOGIA, 2020, 56 (03): : 149 - 156
  • [48] Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model
    Jiang, Yufeng
    Lv, Hailong
    Huang, Shanshan
    Tan, Huiping
    Zhang, Yinong
    Li, He
    NEUROLOGICAL RESEARCH, 2011, 33 (03) : 331 - 336
  • [49] The use of unlicensed bone marrow-derived platelet lysate-expanded mesenchymal stromal cells in colitis: a pre-clinical study
    Salmenkari, Hanne
    Laitinen, Anita
    Forsgard, Richard A.
    Holappa, Mervi
    Linden, Jere
    Pasanen, Lauri
    Korhonen, Matti
    Korpela, Riitta
    Nystedt, Johanna
    CYTOTHERAPY, 2019, 21 (02) : 175 - 188
  • [50] Comparison of Adipose-Derived and Bone Marrow Mesenchymal Stromal Cells in a Murine Model of Crohn's Disease
    Xie, Minghao
    Qin, Huabo
    Luo, Qianxin
    He, Xiaosheng
    He, Xiaowen
    Lan, Ping
    Lian, Lei
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (01) : 115 - 123